Antios Therapeutics’ hep B candidate gets another round of applause from investors, closing out a $171M megaround

Antios Therapeutics, the Atlanta biotech that was the brainchild of former hep C pioneer Pharmasset executive and former Antios CEO Abel De La Rosa, announced this morning that the biotech raised $75 million in a Series B-1, ending the firm’s Series B round.

After the biotech...

Click to view original post